What Is Belimumab and How Is It Used to Treat Lupus?

Belimumab is a biologic medication that works by blocking a protein called B-lymphocyte stimulator (BLyS), which fuels the overactive immune cells responsible for much of the damage in systemic lupus erythematosus, commonly known as lupus. It was the first drug specifically developed and approved for lupus in more than 50 years when it reached the market in 2011, and it remains one of only a handful of biologics approved for the disease. Belimumab is not a standalone treatment; it is added on top of the standard medications a person with lupus already takes, and the evidence for that combination approach has grown substantially over the past decade.

How Belimumab Works

Lupus is driven in large part by B cells, a type of immune cell that produces antibodies. In a healthy immune system, B cells target invaders like bacteria and viruses. In lupus, B cells go haywire and produce autoantibodies that attack the body’s own tissues, causing inflammation in the joints, skin, kidneys, and other organs. A protein called BLyS (also known as BAFF) acts as a survival signal for these B cells. People with lupus tend to have elevated levels of BLyS circulating in their blood, and higher BLyS levels correlate with more autoantibodies and more active disease.¹ BLyS is not unique to lupus; elevated levels have also been detected in people with other autoimmune conditions like Sjögren’s syndrome and rheumatoid arthritis.²

Belimumab is a monoclonal antibody, meaning it was engineered to bind to one specific target. It latches onto soluble BLyS before BLyS can reach B cells, effectively cutting off a key survival signal. Without that signal, the problematic B cells gradually decline. This does not wipe out the immune system the way some older treatments can. Instead, it selectively trims the B-cell populations most dependent on BLyS for survival, including the short-lived plasma cells that churn out autoantibodies. Over weeks and months, autoantibody levels drop, complement proteins (markers of immune activity that are often depleted in active lupus) begin to normalize, and disease activity tends to decrease.³

What the Pivotal Trials Showed

Belimumab’s approval rested primarily on two large phase III trials known as BLISS-52 and BLISS-76, which together enrolled thousands of patients with active, autoantibody-positive lupus. In BLISS-76, the higher dose of belimumab (10 mg/kg intravenously) plus standard therapy produced a significantly better response at one year compared with standard therapy plus placebo, with about 43% of belimumab patients meeting the primary response measure versus roughly 34% on placebo.⁴ That difference may look modest, but lupus is a disease where partial control is the norm and full remission is rare. The response measure itself was strict, requiring improvement in disease activity without worsening in any new organ system and without an increase in steroid dose.

A closer look at the responders revealed meaningful clinical differences. Those who met the response threshold were far more likely to have reduced their steroid doses and far less likely to have needed a steroid increase. They also experienced larger drops in disease activity scores and better preservation of organ function.⁵ So while the gap between belimumab and placebo was not enormous in percentage terms, the people who did respond experienced real, clinically meaningful benefits.

Intravenous Versus Subcutaneous Dosing

Belimumab originally came only as an intravenous infusion given at a clinic. The standard schedule is infusions at weeks zero, two, and four, then once every four weeks after that, at a dose based on body weight (10 mg/kg). Each infusion takes about an hour, plus observation time afterward. For people already spending significant time managing their lupus, monthly clinic visits can be burdensome.

A subcutaneous (self-injected) formulation was later approved. The dose is a flat 200 mg injected weekly using a prefilled syringe or autoinjector at home. Pharmacokinetic modeling showed that the weekly subcutaneous dose produces blood levels comparable to the monthly intravenous infusion at steady state, with largely overlapping concentration ranges.⁶ For many patients, the convenience of home injection makes treatment more sustainable. The choice between the two formulations is typically a conversation between a patient and their rheumatologist, influenced by preference, insurance coverage, and how comfortable someone is with self-injection.

Lupus Nephritis

Kidney involvement, known as lupus nephritis, is one of the most serious complications of lupus and a major driver of long-term organ damage. For years, belimumab’s role in kidney disease was uncertain because the original BLISS trials excluded patients with severe active nephritis. That changed with the BLISS-LN trial, a two-year study specifically in lupus nephritis patients.

At two years, significantly more patients receiving belimumab on top of standard nephritis therapy achieved a primary kidney response compared with placebo (43% versus 32%), and complete kidney responses were also higher in the belimumab group (30% versus 20%).⁷ An open-label extension of that trial showed that response rates continued to climb after the initial two years, including among patients who had originally been on placebo and then switched to belimumab.⁸ A secondary analysis found that belimumab was most effective in patients who had proliferative lupus nephritis and whose urine protein levels at baseline were below a certain threshold, suggesting that earlier use, before kidney damage becomes severe, may yield the best results.⁹

Based on this evidence, current European League Against Rheumatism (EULAR) guidelines now recommend considering add-on belimumab for active lupus nephritis alongside the standard induction drugs.¹⁰

The Steroid-Sparing Effect

One of belimumab’s most practically important benefits has nothing to do with lupus directly. It has to do with steroids. Corticosteroids like prednisone remain the fastest way to tamp down a lupus flare, but long-term steroid use causes a cascade of its own problems: weight gain, bone thinning, diabetes, cataracts, infections, and cardiovascular disease. A major goal in lupus management is getting steroid doses as low as possible, ideally off them entirely.

Data from the BLISS-52 trial showed that patients on the higher belimumab dose were significantly more likely to reduce their prednisone dose and to sustain that reduction for at least 12 weeks compared with placebo.¹¹ Real-world data from clinical practice tell a similar story. An observational study of lupus patients starting belimumab found that the median prednisone dose dropped from 10 mg per day at baseline to 5 mg at 12 months, with the proportion of patients on very low doses or off prednisone altogether climbing steadily over two years.¹² For someone who has been on moderate-to-high steroid doses for years, that kind of reduction can be transformative in terms of daily side effects and long-term health.

Preventing Long-Term Organ Damage

Lupus does cumulative damage over time, tracked clinically by a scoring system that tallies irreversible harm to organs like the kidneys, heart, lungs, and eyes. A post hoc analysis comparing belimumab-treated patients against matched patients on standard therapy alone found that over five years, belimumab was associated with significantly less accumulation of organ damage. Patients on belimumab were roughly 60% less likely to progress to a higher damage score in any given year of follow-up.¹³ Open-label extension studies and propensity-matched analyses have reinforced this finding.¹⁴ The organ-damage reduction is likely driven by the combination of better disease control and lower steroid exposure, since both active disease and chronic steroid use contribute to cumulative damage.

Safety Over the Long Term

Because belimumab deliberately weakens part of the immune system, the obvious concern is infection risk. In the original trials and in a seven-year open-label extension, infection rates actually decreased over time rather than climbing. Serious infection rates peaked in the first year (around 8 per 100 patient-years) and fell in subsequent years. Severe drops in immunoglobulin levels (a sign of excessive immune suppression) remained uncommon, occurring in only about 1% to 3% of patients, and were not associated with higher infection rates in adults.¹⁵

The picture requires more caution in certain populations. A study of pediatric patients with refractory lupus nephritis receiving belimumab found that infection incidence was higher in the belimumab group than in controls, with some children needing immunoglobulin infusions to compensate for low IgG levels.¹⁶ This underscores the importance of monitoring immunoglobulin levels, particularly in children and in patients on multiple immunosuppressants.

Early in belimumab’s development, there were concerns about a possible link to depression and suicidal thoughts, partly because lupus itself carries a high psychiatric burden. A meta-analysis of randomized controlled trials found no significantly elevated risk of serious psychiatric disorders, depression, or suicidal ideation with belimumab compared with placebo.¹⁷ Prescribing labels still recommend monitoring for mood changes, which is reasonable given the overall mental health burden of the disease, but the evidence does not support belimumab as a specific driver of psychiatric risk.

Who Responds Best

Belimumab does not work equally well for everyone, and identifying the right candidates matters. A large real-world study from Italy found that the strongest predictors of a good response at one and two years were high baseline disease activity (a common activity score of 10 or above), the presence of joint inflammation (polyarthritis), and being on a prednisone dose of at least 7.5 mg per day at the start of treatment.¹⁸ In practical terms, this means belimumab tends to shine in patients who have active, flaring disease with prominent musculoskeletal symptoms and who are struggling to get their steroids down. It is less clearly useful in patients with low-grade smoldering disease or those whose lupus is already well controlled on standard drugs.

Serological markers also help. The drug’s registration trials required autoantibody positivity (specifically anti-nuclear antibody or anti-double-stranded DNA antibodies), and the approved indication reflects this. Patients with low complement levels and high autoantibody titers at baseline, indicating a more immunologically active disease, tend to show the most pronounced serological improvements on belimumab.³

Belimumab in Children

Childhood-onset lupus tends to be more aggressive than the adult form, with higher rates of kidney involvement and organ damage. Belimumab became the first biologic approved for childhood lupus based on the PLUTO trial, which enrolled children aged 5 to 17. More belimumab-treated children met the primary response measure than those on placebo (about 53% versus 44%), and belimumab reduced the risk of severe flare by roughly 64%.¹⁹ Serious adverse events were actually less common in the belimumab group. The trial was relatively small, so some of its endpoints did not reach conventional statistical significance, but the overall direction of the results was consistent with the adult data, and pharmacokinetic analysis confirmed that the drug behaves similarly in children.²⁰

Combining Belimumab With Rituximab

Rituximab is another biologic that targets B cells, but it works differently: it directly depletes them rather than cutting off their survival signal. Rheumatologists have long wondered whether using both drugs together, or one after the other, could produce deeper and more durable B-cell suppression. The idea is appealing in theory but proved complicated in practice.

The BLISS-BELIEVE trial tested a sequence in which patients started belimumab and then either continued belimumab alone or added a single cycle of rituximab. Adding rituximab did not significantly improve the primary disease-control endpoint at one year.²¹ A separate smaller trial, however, took the opposite sequence: patients received rituximab first, then were randomized to belimumab or placebo. In that trial, belimumab after rituximab significantly lowered autoantibody levels and reduced the risk of severe flare compared with placebo, while also suppressing B-cell repopulation more effectively.²² The takeaway, at least so far, is that the order may matter: giving belimumab after rituximab to prevent B cells from rebounding seems more promising than the reverse sequence.

Impact on Quality of Life and Fatigue

Lupus fatigue is one of the most debilitating symptoms patients report, and it is notoriously resistant to treatment. In the BLISS trials, patients on belimumab reported significantly greater improvements in physical health, mental health, and fatigue scores compared with placebo.²³ Longer-term follow-up showed that these improvements were sustained. At six years of treatment, average physical and mental health scores had improved by amounts that exceeded the threshold considered clinically meaningful, and fatigue scores hovered around the same threshold.²⁴

A cohort study comparing lupus patients before and after starting belimumab found improvements across every domain of quality-of-life questionnaires, including physical function, emotional wellbeing, pain, and social functioning. After treatment, their scores approached those of a healthy comparison group.²⁵ These quality-of-life data are sometimes more persuasive to patients and clinicians than abstract response indices, because they capture what daily life actually feels like.

Pregnancy and Breastfeeding Considerations

Many people with lupus are women of childbearing age, so the question of whether belimumab is safe during pregnancy comes up frequently. Currently, manufacturers recommend stopping belimumab at least four months before a planned pregnancy, because as an IgG antibody, it crosses the placenta and reaches the fetus. A recent case series of three women who continued belimumab throughout pregnancy found that cord blood and neonatal serum concentrations of belimumab were comparable to maternal levels, confirming substantial placental transfer. The neonates had lower-than-expected B-cell counts at birth, though their immunoglobulin levels and T-cell counts were within normal ranges. One infant was diagnosed with a congenital urinary tract anomaly, but the others were healthy. Belimumab concentrations in breast milk were low, and vaccinated infants who were breastfed by treated mothers had no adverse events.²⁶

This is still very preliminary data from just three pregnancies, so it does not change the general recommendation to stop before conceiving. But the finding that breast milk transfer is low is somewhat reassuring for women who resume belimumab postpartum and wish to breastfeed. The broader challenge is that lupus flares are themselves dangerous during pregnancy, so stopping an effective treatment is always a calculated risk. This is a decision that requires close coordination between a rheumatologist and an obstetrician.

Monitoring Serological Markers on Treatment

An interesting wrinkle for clinicians managing patients on belimumab is that the drug itself changes the lab values traditionally used to monitor lupus activity. Complement levels tend to rise and stabilize on belimumab, and autoantibody titers tend to fall. That is partly the point, but it complicates the picture when a rheumatologist is trying to decide whether a worsening symptom represents a true flare or something unrelated. A recent study found that while complement and anti-dsDNA levels improved on belimumab as expected, their usefulness for predicting flares shifted. Anti-dsDNA positivity remained a meaningful predictor of flares, but low complement levels lost their usual predictive value. Low C3 showed only a borderline association with moderate-to-severe flares, while C4 levels were not associated with flares at all in patients on belimumab.²⁷ Clinicians may need to rely more heavily on clinical symptoms and anti-dsDNA antibodies rather than complement levels when assessing disease activity in patients on this drug.

Cost and the Case for Early Treatment

Belimumab is expensive, and cost is a genuine barrier. Across multiple countries, economic evaluations have generally found belimumab to be cost-effective, though results depend on the healthcare system and the willingness-to-pay threshold used. A systematic review of economic analyses across several countries concluded that belimumab showed a consistently favorable cost-effectiveness profile, with treatment effectiveness and discontinuation rates having the biggest influence on the numbers.²⁸

A recent modeling study asked whether starting belimumab earlier in the disease course, rather than waiting until disease worsens, would be economically justified. Over a 15-year horizon, early initiation actually saved money compared with delayed initiation, roughly $126,000 less per patient in total costs, while also producing slightly better health outcomes.²⁹ The savings come primarily from fewer hospitalizations, fewer flares requiring expensive rescue therapy, and less accumulated organ damage. The implication is straightforward: if a patient meets the criteria for belimumab, waiting does not save the healthcare system money, and it may cost the patient organ function in the meantime.